Choose Mitigare® and Generic Colchicine 0.6 mg Capsules

Affordable, Effective, Accessible Gout Flare Prevention1,2

 

dollar sign icon

Affordable
Options

flame icon

Effective Gout
Flare Prevention

Wider
Accessibility

 

Affordable Options—Branded and Generic

  • Lower-priced colchicine products—Mitigare® and Generic Colchicine Capsules1

Effective Gout Flare Prevention

  • In a 6-month study of 43 patients with recurrent gout, the prophylactic use of colchicine resulted in an 82% reduction in frequency of gout flares.2
  • Colchicine 0.6 mg has been shown to be well tolerated.2 The most common adverse reactions experienced by patients taking colchicine once or twice daily are gastrointestinal symptoms, including diarrhea, nausea, vomiting and abdominal pain.3

Wider Accessibility

  • Mitigare® and Generic Colchicine Capsules are covered by many health insurance plans.
Find out where to fill your Mitigare® (colchicine) prescription.

Where to Fill Your Prescription

You’ll find convenient options when it comes to filling your Mitigare® or Generic Colchicine Capsules prescription.

FIND A PHARMACY

References

  1. First Databank. AnalySource® website. Available at: https://www.analysource.com/. Accessed January 6, 2020.
  2. Borstad GC, Bryant LR, Abel MP, Scroggie DA, Harris MD Alloway JA. Colchicine for prophylaxis of acute flares when initiating allopurinol for chronic gouty arthritis. J Rheumatol. 2004 Dec;31(12):2429-2432.
  3. Mitigare® (Colchicine) 0.6 mg Capsules [prescribing information]. Columbus OH: West-Ward Columbus, Inc.; 2019.

Important Safety Information for Mitigare® (colchicine) 0.6 mg capsules

  • Colchicine 0.6 mg capsules are contraindicated in patients with renal or hepatic impairment who are currently prescribed drugs that inhibit both P-gp and CYP3A4. Combining these dual inhibitors with colchicine in patients with renal or hepatic impairment has resulted in life-threatening or fatal colchicine toxicity. Patients with both renal and hepatic impairment should not be given Mitigare®.
  • Fatal overdoses have been reported with colchicine in adults and children. Keep Mitigare® out of the reach of children.
  • Blood dyscrasias such as myelosuppression, leukopenia, granulocytopenia, thrombocytopenia, and aplastic anemia have been reported with colchicine used in therapeutic doses.
  • Monitor for toxicity and if present consider temporary interruption or discontinuation of colchicine.
  • Drug interaction with dual P-gp and CYP3A4 inhibitors: Co-administration of colchicine with dual P-gp and CYP3A4 inhibitors has resulted in life-threatening interactions and death.
  • Neuromuscular toxicity and rhabdomyolysis may occur with chronic treatment with colchicine in therapeutic doses, especially in combination with other drugs known to cause this effect. Patients with impaired renal function and elderly patients (including those with normal renal and hepatic function) are at increased risk. Consider temporary interruption or discontinuation of Mitigare®.
  • The most commonly reported adverse reactions with colchicine are gastrointestinal symptoms, including diarrhea, nausea, vomiting, and abdominal pain.

Indication

Mitigare® is indicated for prophylaxis of gout flares in adults. The safety and effectiveness of Mitigare for acute treatment of gout flares during prophylaxis has not been studied.

Mitigare® is not an analgesic medication and should not be used to treat pain from other causes.

For Full Prescribing Information please CLICK HERE and for Medication Guide CLICK HERE.

You are encouraged to report negative side effects of prescription drugs to the FDA.

Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Manufactured by: West-Ward Columbus Inc., Columbus, OH 43228

Read More...

Important Safety Information for Mitigare® (colchicine) 0.6 mg capsules

  • Colchicine 0.6 mg capsules are contraindicated in patients with renal or hepatic impairment who are currently prescribed drugs that inhibit both P-gp and CYP3A4.